List of Fabior drug patents

Fabior is owned by Mayne Pharma.

Fabior contains Tazarotene.

Fabior has a total of 3 drug patents out of which 0 drug patents have expired.

Fabior was authorised for market use on 11 May, 2012.

Fabior is available in aerosol, foam;topical dosage forms.

Fabior can be used as topical treatment of acne vulgaris in patients 12 years of age or older.

The generics of Fabior are possible to be released after 24 February, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568859 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

US10688071 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

US8808716 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 11 May, 2012

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in